SBRT for Oligoprogression Improves Outcomes in NSCLC but Not Breast Cancer
Treating oligoprogression with SBRT improved progression-free survival in patients with lung cancer but not in those with breast cancer.
Treating oligoprogression with SBRT improved progression-free survival in patients with lung cancer but not in those with breast cancer.
Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Delivery of radiation to the celiac plexus can decrease pain and opioid use among patients with pancreatic cancer, a phase 2 study suggests.
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
A concurrent radiation boost produces comparable outcomes as a sequential boost in patients with high-risk breast cancer, a phase 3 study suggests.
Adding oral S-1 chemotherapy to radiotherapy can improve outcomes in elderly patients with inoperable esophageal squamous cell carcinoma.
Mepitel Film reduced the rate of grade 2-3 radiation dermatitis in patients with breast cancer.
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.